Skip to content

Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program

Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program: A Hybrid Type 1 Effectiveness-Implementation Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06236100
Enrollment
360
Registered
2024-02-01
Start date
2023-11-29
Completion date
2027-09-29
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Childhood Experiences, Substance-Related Disorders

Keywords

Adverse Childhood Experiences, Strengthening Families Program, Family Advocate, Community-level interventions, Hybrid Type 1 Design, Mixed-Method Evaluation, Effectiveness Trial, Cluster Randomized Controlled Trial, Process Evaluation, Cost Evaluation

Brief summary

Primary Objective: Conduct a rigorous evaluation of a prevention-based intervention designed to mitigate the harms of adverse childhood experiences (ACEs) exposure and prevent future ACEs, substance use, and overdose within 36 communities experiencing a disproportionate burden of substance use and ACEs. The study has three aims: (1) use a cluster randomized controlled trial to test effectiveness of the Strengthening Families Program (SFP) + Family Advocate (FA) intervention on substance use, overdose, and ACEs in 18 communities compared with SFP-only in 18 communities; (2) conduct a robust process evaluation informed by the Consolidated Framework for Implementation Research (CFIR) to explore implementation barriers and facilitators; and (3) conduct a cost evaluation to accurately estimate the costs required to implement SFP and SFP+FA and assess the cost-effectiveness of SFP+FA relative to SFP alone. Findings will provide a roadmap about the best ways to help disproportionately affected communities prevent substance use, overdose, and ACEs.

Detailed description

Early exposure to Adverse Childhood Experiences (ACEs), such as parental substance use, increases the likelihood of future substance use and drug overdose, resulting in an intergenerational cycle of substance-related ACEs that can continue indefinitely if left uninterrupted. Community-level interventions may moderate the relationship between ACEs and substance use by providing an array of family support services and treatments to reduce disparities and improve reach and service linkages in the community. Although research suggests that effectively decreasing the prevalence and impact of ACEs and substance use requires addressing both family- and community-level factors in tandem, there is a critical gap within the evidence base pertaining to interventions that effectively integrate the two factors to prevent substance use and ACEs. RTI International and its partners, the New Jersey Prevention Network and RWJBarnabas Health, will evaluate an intervention integrating New Jersey's established, evidence-based Strengthening Families Program (SFP) with clinically trained, trauma-informed Family Advocates (FAs) who will assist families (i.e., parents/caregivers and youth between the ages of 12 and17) in accessing community resources. Specifically, this study will use a Hybrid Type 1 effectiveness-implementation design across 36 New Jersey communities experiencing a disproportionate burden of substance use and ACEs.

Interventions

BEHAVIORALStrengthening Families Program + Family Advocate

This intervention will integrate clinically trained, trauma-informed Family Advocates (FA) into the established, evidence-based Strengthening Families Program (SFP). Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks. FAs will assist families in accessing community resources for substance use and Adverse Childhood Experiences (ACE) prevention and treatment.

BEHAVIORALStrengthening Families Program

This intervention consists of the SFP7-17 Group Class Curriculum. Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks.

Sponsors

RTI International
Lead SponsorOTHER
New Jersey Prevention Network
CollaboratorUNKNOWN
RWJBarnabas Health Institute for Prevention and Recovery
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
7 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

To be eligible to participate in this study, a family must meet all of the following criteria: * Either reside in, or attend SFP meetings, within one of the 36 New Jersey communities with disproportionate levels of ACEs and substance use disorder (SUD) issues that are assigned to either the treatment or control conditions via the study's cluster randomized controlled trial design * Meet family eligibility requirements: * One or more adult caregivers * One or more adolescents, ages 7 to 17 * Caregiver provision of signed and dated informed consent form * For children, informed assent and parental permission via the informed consent to participate in the study * Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study * Willingness to adhere to the regimens of the SFP and FA interventions * Access to necessary resources for participating in a technology-based intervention (i.e., computer, smart phone, internet access)

Exclusion criteria

A family who meets any of the following criteria will be excluded from participation in this study: * Caregiver has previously completed SFP with one or more children, ages 7 to 17 * Intellectual disabilities (i.e., cognitive impairments that would prohibit the completion of the SFP curriculum or data collection instruments) * Language difficulties (caregivers and children must read and understand spoken English)

Design outcomes

Primary

MeasureTime frameDescription
Substance use prevalenceBaseline, intervention completion (ranging from 10 to 14 weeks), and 6-month post-intervention follow-upMeasure of substance use prevalence among parents/caregivers and youth derived from 4 questions included on the SFP adult and SFP youth pre-test, post-test, and 6-month follow-up surveys. These 4 questions focus on whether various substances were ever used, used in the past 30 days, on how many day substances were used (if any), and which substances were used.
Substance use perceptions of harmBaseline, intervention completion (ranging from 10 to 14 weeks), and 6-month post-intervention follow-upMeasure of substance use perceptions of harm among parents/caregivers and youth derived from 3 questions included on the SFP adult and SFP youth pre-test, post-test, and 6-month follow-up surveys. These 3 questions focus on perceptions of harm associated with alcoholic beverages, marijuana, and prescription drugs.
Referrals to clinical servicesBaseline, intervention completion (ranging from 10 to 14 weeks), and 6-month post-intervention follow-upMeasure of rate of referrals to clinical services among participating families using the study's Weekly Clinical and Non-Clinical Services Referral Log
Referrals to non-clinical servicesBaseline, intervention completion (ranging from 10 to 14 weeks), and 6-month post-intervention follow-upMeasure of rate of referrals to non-clinical services among participating families using the study's Weekly Clinical and Non-Clinical Services Referral Log

Secondary

MeasureTime frameDescription
ACEs prevalenceBaseline and 6-month post-intervention follow-upMeasure of ACEs prevalence among parents/caregivers and youth in participating families using 3 questions from the study's pre-test and 6-month post-test ACEs/Social Needs Screener. These 3 questions focus on the prevalence of the three main ACEs categories of abuse, neglect, and household challenges.
Social needs prevalenceBaseline and 6-month post-intervention follow-upMeasure of social needs prevalence among parents/caregivers and youth in participating families using 18 questions from the study's pre-test and 6-month post-test ACEs/Social Needs Screener. These 18 questions correspond to 5 social determinants of health domains (including house, food security, transportation, finances, and personal safety) from the American Academy of Family Physicians' social determinants of health screening tool.
Substance use riskBaseline, intervention completion (ranging from 10 to 14 weeks), and 6-month post-intervention follow-upMeasure of substance use risk among parents/caregivers and youth derived from 3 questions included on the SFP adult and SFP youth pre-test, post-test, and 6-month follow-up surveys. These 3 questions focus on ease of access to different types of substances that may increase risk of substance use.
System linkagesBaseline and 6-month post-intervention follow-upMeasures of change in clinical and non-clinical referral networks (such as changes in network size, edges, density, centrality, reciprocity, triadic closure, and assortativity) using questions included on the study's pre-test and 6-month post-test community service provider survey
Average start-up costPre-implementationMeasure of average cost per agency of starting up a program to deliver the intervention or active comparator using data from the study's Costing Instrument and Interview and administrative data from the New Jersey Prevention Network
Intervention costIntervention start to intervention completion (ranging from 10 to 14 weeks)Measure of intervention cost at the participant level of delivering the intervention or active comparator using data from the study's Costing Instrument and Interview, 4 questions from the Intervention Cost Survey for SFP Facilitators, and 2 questions from the Intervention Cost Survey for Family Advocates
Cost per service referralIntervention start to intervention completion (ranging from 10 to 14 weeks)Measure of cost per service referral at the participant level using data from outcomes 6, 7, and 12, comparing cost per service referral for treatment and active comparator

Countries

United States

Contacts

CONTACTAndrea L. Zapcic, BA
Andrea@njpn.org908-433-2064
CONTACTBrittany Simon, MA
Brittany.Simon@rwjbh.org201-218-5551
PRINCIPAL_INVESTIGATORPhillip W. Graham, DrPH

RTI International

PRINCIPAL_INVESTIGATORDallas J Elgin, PhD

RTI International

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026